Even though many challenges must be overcome before widespread adoption can occur, there is still much promise on the horizon for biosimilars.
Omar Hafez, MS, MBA
Advertisement
Articles by Omar Hafez, MS, MBA
Advertisement
Latest Updated Articles
Signs Point to Better Market Conditions for BiosimilarsSeptember 5th 2019
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
3
META 10-19 Elicits High Complete Response Rate at Ultra-Low Doses in High-Risk R/R DLBCL
4
Sonrotoclax and Next-Generation BCL-2 Inhibitors for Treating CLL
5